{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:29:51Z","timestamp":1768512591341,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T00:00:00Z","timestamp":1255392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p><jats:bold>Abstract.\u2002<\/jats:bold> Holme I, Fayyad R, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Holdaas H, Pedersen TR, On behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (Centre of Preventive Medicine, Oslo, Norway; \u00c5rhus University Hospital, \u00c5rhus, Denmark; Academic Hospital Amsterdam, Amsterdam, The Netherlands; University Hospital, Link\u00f6ping, Sweden; Helsinki University Central Hospital, Helsinki, Finland; Oslo University Hospital, Rikshospitalet, Oslo, Norway; Pfizer Sweden, Sollentuna, Sweden; and Pfizer Inc., New York, NY, USA). Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: Results from the IDEAL trial. <jats:italic>J Intern Med<\/jats:italic> 2010; <jats:bold>267<\/jats:bold>:567\u2013575.<\/jats:p><jats:p><jats:bold>Objectives.\u2002<\/jats:bold> In Incremental Decrease in Endpoints through Aggressive Lipid\u2010lowering (IDEAL), we compared cardiovascular outcomes in patients with and without chronic kidney disease (CKD) (estimated glomerular filtration rate &lt;60\u2003mL\u2003min<jats:sup>\u22121<\/jats:sup>\u20031.73\u2003m<jats:sup>\u22122<\/jats:sup>) and analysed relationships between lipoprotein components (LC) and major coronary events (MCE) and other cardiovascular (CV) events.<\/jats:p><jats:p><jats:bold>Design.\u2002<\/jats:bold> Exploratory analysis of CV endpoints in a randomized trial comparing high dose of atorvastatin to usual dose of simvastatin on MCE.<\/jats:p><jats:p><jats:bold>Settings.\u2002<\/jats:bold> Patients with CKD were compared with the non\u2010CKD patients. Cox regression models were used to study the relationships between on\u2010treatment levels of LC and incident MCE.<\/jats:p><jats:p><jats:bold>Findings.\u2002<\/jats:bold> Chronic kidney disease was strongly associated with cardiovascular end\u2010points including total mortality. In patients with CKD, a significant benefit of high dose atorvastatin treatment was found for any CV events, stroke and peripheral artery disease, but not for MCE. However, all cardiovascular end\u2010points except stroke and CV mortality were reduced in the non\u2010CKD group. Differential changes in LC or relationships to LC could not explain the different treatment outcomes in MCE in the two groups.<\/jats:p><jats:p><jats:bold>Interpretation.\u2002<\/jats:bold> Chronic kidney disease was a powerful risk factor for all cardiovascular end\u2010points. The reason why the significant reductions achieved by high\u2010dose statin treatment in most CV end\u2010points in the non\u2010CKD group were only in part matched by similar reductions in the CKD patients is not apparent. This difference did not result from differential changes in or relations to LC, but limited power may have increased the possibility of chance findings.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2009.02176.x","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T21:27:38Z","timestamp":1255469258000},"page":"567-575","source":"Crossref","is-referenced-by-count":21,"title":["Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial"],"prefix":"10.1111","volume":"267","author":[{"given":"I.","family":"Holme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fayyad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Faergeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Tikkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Holdaas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. R.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,4]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1884"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000107565.17553.71"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000146378.65439.7A"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.11.043"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.06.003"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00010"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000143892.84582.60"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.11.072"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.11.025"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.06.003"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.19.2437"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890801964955"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/08037059209077502"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000193841.43474.ec"},{"key":"e_1_2_9_17_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/clinchem\/39.5.773","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A\u2010I and B. III. Comparability of apolipoprotein A\u2010I values by use of international reference material","volume":"39","author":"Marcovina SM","year":"1993","journal-title":"Clin Chem"},{"key":"e_1_2_9_18_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/40.4.586","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A\u2010I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material","volume":"40","author":"Marcovina SM","year":"1994","journal-title":"Clin Chem"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.10.029"},{"key":"e_1_2_9_21_2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF heart protection study of cholesterol\u2010lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial","volume":"361","author":"Heart Protection Study Collaborative group","year":"2003","journal-title":"Lancet"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.11.010"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00862.x"},{"issue":"2","key":"e_1_2_9_25_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2006.12.001","volume":"49","author":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","year":"2007","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2009.02176.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2009.02176.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T04:42:54Z","timestamp":1698900174000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2009.02176.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,4]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2796.2009.02176.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02176.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,4]]}}}